摘要
食管胃结合部腺癌是发生于食管和胃交界处的消化系统恶性肿瘤,近年愈受重视并有将其归为一种特殊类型肿瘤的趋势。现有的治疗手段远期疗效仍不尽如人意,靶向治疗为患者生存期延长提供了新的可能。而当下已经投入临床应用的主要是抗HER2靶向药物与抗血管生成药物。本文将针对食管胃结合部腺癌的靶向治疗进展作一综述。
Adenocarcinoma of the esophagogastric junction(AEG)is a kind of digestive malignant tumor,which locates in esophagogastric junction,is increasingly important and tends to be a specific type of cancer.Long-term results of existing treatments are still poor,while targeted therapies offer new possibilities to improve this situation.Currently,approved targeted therapies are mainly anti-HER2 and anti-angiogenic agents.Herein,we give an overview of advances in targeted therapies for adenocarcinoma of the esophagogastric junction.
作者
陈键
何裕隆
CHEN Jian;HE Yu-long(Gastrointestinal Surgery,the First Affiliated Hospial of Sun Yat-Sen University,Guangzhou 510080,China;The Center of Digetive Disease,the Seventh Affiliated Hospital of Sun Yat-Sen University,Shenzhen 518000,China)
出处
《消化肿瘤杂志（电子版）》
2019年第4期317-324,共8页
Journal of Digestive Oncology(Electronic Version)
